Meloxicam injection - Recro Pharma

Drug Profile

Meloxicam injection - Recro Pharma

Alternative Names: N-1539; NanoCrystal® meloxicam

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Elan Drug Delivery Inc
  • Developer Recro Pharma
  • Class 2 ring heterocyclic compounds; Amides; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines; Thiazoles
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Postoperative pain

Most Recent Events

  • 05 Oct 2017 The US FDA sets PDUFA date of 26/05/2018 for NDA review for Postoperative pain
  • 28 Sep 2017 US FDA accepts NDA for meloxicam injection for Postoperative pain for review
  • 05 Sep 2017 Adverse events data from a phase III trial in Post operative pain released by Recro Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top